Related references
Note: Only part of the references are listed.Next generation of small molecules in inflammatory bowel disease
Pablo Olivera et al.
GUT (2017)
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Julian Panes et al.
GUT (2017)
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Prospective Validation of Deep Learning for Polyp Auto-detection during Colonoscopy
Pu Wang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
Christopher Ma et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Modulation of sphingosine-1-phosphate in inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
AUTOIMMUNITY REVIEWS (2017)
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
G. Monteleone et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
Silvio Danese et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2016)
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
Florence Namour et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
William J. Sandborn et al.
GASTROENTEROLOGY (2016)
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris et al.
JOURNAL OF CROHNS & COLITIS (2016)
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis
P. Rutgeerts et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
Mahmoud H. Mosli et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
Julian Panes et al.
BMC GASTROENTEROLOGY (2015)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
Naoki Yoshimura et al.
GASTROENTEROLOGY (2015)
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy
Richard L. Proia et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Giovanni Monteleone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A phase II study of laquinimod in Crohn's disease
Geert D'Haens et al.
GUT (2015)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
First Multicenter Study of Modified Release Phosphatidylcholine LT-02 in Ulcerative Colitis: A Randomized, Placebo-Controlled Trial in Mesalazine-Refractory Courses
Max Karner et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Lupus Nephritis: The Evolving Role of Novel Therapeutics
Brad H. Rovin et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2014)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
Brigid S. Boland et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases
Masayuki Saruta et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2014)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
Targets for Future Clinical Trials in Huntington's Disease: What's in the Pipeline?
Edward J. Wild et al.
MOVEMENT DISORDERS (2014)
Inflammatory pathways of importance for management of inflammatory bowel disease
Jannie Pedersen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Defining a role for laquinimod in multiple sclerosis
Bernd C. Kieseier
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
Cumulative Incidence of Second Intestinal Resection in Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Studies
Alexandra D. Frolkis et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
Channa Kolb-Sobieraj et al.
NEUROLOGY AND THERAPY (2014)
Modulators of the Sphingosine 1-phosphate receptor 1
Mariangela Urbano et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
Valerie Jolivel et al.
BRAIN (2013)
Short-Chain Fatty Acids Activate GPR41 and GPR43 on Intestinal Epithelial Cells to Promote Inflammatory Responses in Mice
Myung H. Kim et al.
GASTROENTEROLOGY (2013)
Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies
Alexandra D. Frolkis et al.
GASTROENTEROLOGY (2013)
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: The ENTRANCE study
K. R. Herrlinger et al.
JOURNAL OF CROHNS & COLITIS (2013)
The burden of inflammatory bowel disease in Europe
Johan Burisch et al.
JOURNAL OF CROHNS & COLITIS (2013)
Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice
Toshihiko Sugiura et al.
Journal of Crohns & Colitis (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Mehmet Coskun et al.
PHARMACOLOGICAL RESEARCH (2013)
The structure and function of the S1P1 receptor
Catherine O'Sullivan et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study
Gilaad G. Kaplan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Peter Schafer
BIOCHEMICAL PHARMACOLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis
Elias Toubi et al.
JOURNAL OF NEUROIMMUNOLOGY (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Nicholas J. Talley et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: An Australian and New Zealand experience
Ian C. Lawrance et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
Christiane Wegner et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
Biological Therapies for Inflammatory Bowel Diseases
Paul Rutgeerts et al.
GASTROENTEROLOGY (2009)
Alterations of Phospholipid Concentration and Species Composition of the Intestinal Mucus Barrier in Ulcerative Colitis: A Clue to Pathogenesis
Annika Braun et al.
INFLAMMATORY BOWEL DISEASES (2009)
Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules
David Marsolais et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
Per Bjork et al.
PLOS BIOLOGY (2009)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial
James D. Lewis et al.
GASTROENTEROLOGY (2008)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
SAR, species specificity, and cellular activity of cyclopentene dicarboxylic acid amides as DHODH inhibitors
J Leban et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
RDP58 is a novel and potentially effective oral therapy for ulcerative colitis
S Travis et al.
INFLAMMATORY BOWEL DISEASES (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Interleukin-10 therapy - Review of a new approach
K Asadullah et al.
PHARMACOLOGICAL REVIEWS (2003)
RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis
S Murthy et al.
INFLAMMATION RESEARCH (2002)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease
GH Waetzig et al.
JOURNAL OF IMMUNOLOGY (2002)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
